George Ansstas, M.D.
Washington University School of Medicine
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name George Ansstas, M.D. as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:03 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05060003 · Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following ResectionWashington University School of Medicine · terminated · Stage II Melanoma · principal investigator
- Ph2NCT04318717 · Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal MelanomaWashington University School of Medicine · suspended · Mucosal Melanoma of the Head and Neck · principal investigator
- Ph2NCT03903640 · Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain MetastasisWashington University School of Medicine · terminated · Melanoma With Brain Metastasis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:03 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.